Squarespace to Go Private in $6.9 Billion Transaction With Permira
Cooley advised Accel, a long-standing investor of Squarespace, in connection with Squarespace’s definitive agreement to go private by Permira in an approximately $6.9 billion all-cash transaction. Accel is a global venture capital firm that is the first partner to exceptional teams everywhere, from inception through all phases of private company […]
AGS Announces Definitive Agreement to Be Acquired by Brightstar Capital Partners for $1.1 Billion
Cooley advised PlayAGS (AGS), a global gaming supplier of high-performing slots, tables and interactive products, on its definitive agreement to be acquired by the affiliates of Brightstar Capital Partners for $1.1 billion. AGS shareholders will receive $12.50 per share in cash, a 41% premium to its volume-weighted average share price […]
WSO2 to Be Acquired by EQT
Cooley advised WSO2, a leading provider of application development and identity and access management software to enterprise companies globally, on its agreement to be acquired by EQT’s BPEA Fund VIII (EQT Private Capital Asia). WSO2 joins EQT’s extensive global portfolio of enterprise software companies that already includes firms such as […]
Freshworks Agrees to Acquire Device42
Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – […]
Nuvalence Announces Acquisition by EY
Cooley advised Nuvalence, a technology consultancy firm, on its acquisition by EY to accelerate the delivery of platform engineering, product development, and generative artificial intelligence platform-enabled services to organizations across industries and sectors. Nuvalence Announces Acquisition by EY
Cidara Therapeutics Announces Concurrent Reacquisition of IP Rights to CD388, $240 Million PIPE Financing
Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson […]
Tenet Medicines to Be Acquired by Eliem Therapeutics
Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics (Nasdaq: ELYM), a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. […]
Automattic Acquires Beeper
Cooley advised Automattic, a distributed company with 1,965 users in 93 countries speaking 119 different languages, on its acquisition of Beeper, a universal messaging application that combines 14 different chat networks in one inbox. The transaction represents Automattic’s next step toward combining all online conversations in a safe, secure and […]
Hootsuite to Acquire Talkwalker
Cooley advised Hootsuite, a global leader in social media management, on its definitive agreement to acquire Talkwalker, a Luxembourg-based, top artificial intelligence-powered social listening solution and portfolio company of Marlin Equity Partners. The acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions. Hootsuite to […]
ProfoundBio Announces $1.8 Billion Acquisition by Genmab
Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer […]